The abstract is read at the publisher; the summary is JClub's.
Low-dose interleukin-2 restores CD25hi regulatory T cells in patients with active polymyositis/dermatomyositis, with reduced Treg-IL-2 axis markers compared with healthy controls.
- Why it matters: Inflammatory myopathies may involve a reversible IL-2 availability problem in regulatory T cells, but the Treg-IL-2 axis defect and its recoverability were unclear.
- What they did: The study compared CD4+ T cell subsets in polymyositis/dermatomyositis (n = 20) versus healthy controls (n = 19) and tested IL-2 dose effects on PBMC for 24 hours, plus IL-2 therapy for eight weeks in two refractory patients.
- The result: Patients showed fewer CD25hi Treg and fewer CXCR5+ Treg, especially in active disease, and IL-2 stimulation increased CD25hi Treg and immunoregulatory mRNA; in treated patients, muscle enzymes decreased alongside sustained CD25+ Treg expansion.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.